hrp0094wg8.3 | ESPE Working Group on Turner Syndrome Symposium | ESPE2021

Blood Pressure in Turner Syndrome - a practical approach

Matthews Debbie ,

Females with Turner syndrome (TS) have a reduced life expectancy of about 13 years and a substantial excess mortality; about 50% of this is the result of cardiovascular pathology. Hypertension affects 20-60% of females with TS and is the single most modifiable risk factor for cardiovascular disease. However, hypertension in TS is both under-diagnosed and under-treated. The presentation details a practical approach to monitoring blood pressure and managing hypertension in TS. T...

hrp0095p2-139 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2022

A stormy neonatal course

Brown Katie , Kaninde Abhidhamma , Law James , Nadar Ruchi , Saraff Vrinda , Mohamed Zainaba

Introduction: Neonatal thyrotoxicosis (NT) is rare but potentially life-threatening condition with high mortality risk due to cardiac failure(12-20%). Affected neonates are born to mothers with underlying thyroid pathology. Estimated prevalence of trans-placental transfer of thyroid antibodies occurs 1 in every 70 pregnancies with Graves’ disease. Symptoms in the neonate usually manifest by 10 days of life but this can be as late as day 45. We discuss tw...

hrp0084p2-415 | GH & IGF | ESPE2015

The Pharmacokinetics and Pharmacodynamics of TV-1106, a Once Weekly GH Supplement: Results from a Phase 2 Study of TV-1106 in Adults with GH Deficiency

Cohen-Barak Orit , Christiansen Jens Sendahl , Bidlingmaier Martin , Brown Kurt , Sakov Anat , Anscheutz Gaya , Butler Kathleen

Background: TV-1106 (Teva Pharmaceuticals Ltd) is a genetically fused recombinant GH (rhGH) and human serum albumin in development as a once weekly treatment of GH deficiency (GHD) in children and adults. TV-1106 has an extended duration of action compared to daily rhGH treatment, reducing the frequency of injections.Objective and hypotheses: The pharmacokinetics and pharmacodynamics of TV-1106 were evaluated in phase 2 study using non-compartmental anal...

hrp0084p2-553 | Thyroid | ESPE2015

Efficacy of Supplemental Liothyronine for Patients with Congenital Hypothyroidism and Pituitary Resistance to Thyroid Hormone

Paone Laura , Fleisch Abby F , Feldman Henry , Cappa Marco , Brown Rosalind , Wassner Ari J

Background: Recent guidelines recommend levothyroxine (LT4) monotherapy for all infants with congenital hypothyroidism (CH). However, up to one-third of patients have pituitary resistance to thyroid hormone and, to normalize their TSH, require supranormal circulating levels of T4. Liothyronine (T3) has been proposed as a supplemental therapy for such patients, but data demonstrating its use and efficacy are limited.Object...

hrp0089p3-p126 | Fat, Metabolism and Obesity P3 | ESPE2018

Tracing the Effect of the Melanocortin-4 Receptor Pathway in Obesity: Study Design and Methodology of the TEMPO Registry

Eneli Ihuoma , Xu Jinyu , Fiedorek Fred , Webster Matthew , McCagg Amy , Ayers Kristin , Ploeg Lex Van Der , Garfield Alastair , Estrada Elizabeth

Introduction: The hypothalamic melanocortin-4 receptor (MC4R) pathway plays a vital role in energy balance. Genetic defects in the MC4R pathway may result in severe early onset obesity.Objective: The TEMPO registry (NCT03479437) aims to identify and enroll approximately 1000 participants with rare genetic forms of obesity that are potentially related to key genes, upstream or downstream, of the MC4R. In addition, the TEMPO registry will evaluate the burd...

hrp0086rfc5.2 | Management of Disorders of Insulin Secretion | ESPE2016

Limits of Agreement between HbA1c Levels Measured in Different Laboratories Following the Introduction of the International Federation of Clinical Chemistry and Laboratory Medicine Standardised Values

Arch Barbara , McKay Andrew , Newland Paul , Blair Joanne , Gregory John , Peak Matthew , Didi Mohammed , Thornborough Keith , Gamble Carrol

Background: Between 2011 and 2015, 294 children from 15 UK centres were randomised to the SCIPI study (SubCutaneous Insulin: Pumps or Injections?), which compares insulin delivery by pump to multiple daily injections, during the first year following diagnosis of type I diabetes. HbA1c is measured every 3 months, locally by (1) a ‘point of care’ device or a local laboratory and (2) a central laboratory. Since 2009 HbA1c assays have been calibrated against the Internat...

hrp0084p1-71 | Fat | ESPE2015

Identifying Critical Periods for Maintaining Weight Loss in Obese Children

Peacock Amanda , Mushtaq Talat , Alexander Erin , Truby Helen , Greenwood Darren , Russo Vince , Yau Steven , Werther George , Sabin Matthew

Background: Adults have a weight that is normal for them. This is referred to as their ‘set-point’ for weight. Studies have shown physiological protection of this set-point, explaining why most obese adults who diet eventually regain weight.Objective and hypotheses: We hypothesised that set-points for weight, and their physiological defence, are flexible in childhood but become fixed sometime around puberty. We aimed to show that obese children...

hrp0084p2-359 | Fat | ESPE2015

FTO rs9939609 Polymorphism is Associated with the Presence of Obstructive Sleep Apnoea in Obese Youth

Kao Kung-Ting , Alexander Erin , Harcourt Brooke E , Saffery Richard , Wake Melissa , McCallum Zoe , Werther George , Sabin Matthew

Background: Emerging evidence suggests FTO polymorphisms are associated with obesity-related comorbidities including type 2 diabetes (T2DM), hypertension and polycystic ovarian syndrome (PCOS). However association of FTO with other comorbidities such as obstructive sleep apnoea (OSA) in paediatric populations is less clear.Objective and hypotheses: To investigate the prevalence of obesity-related comorbidities according to FTO genotype in an obese paedia...

hrp0097rfc10.2 | Fetal, neonatal endocrinology and metabolism (to include hypoglycaemia) & Multisystem endocrine disorders | ESPE2023

Utility of Continuous Glucose Monitoring (CGM) during pancreatic surgery in patients with Congenital Hyperinsulinism

Worthington Sarah , Worth Chris , O'Shea Elaine , Ahmad Sumera , Bowler Matthew , Beauve Benoit , Salomon-Estebanez Maria , Banerjee Indraneel

Introduction: Congenital Hyperinsulinism (CHI) is a rare disease of hypoglycaemia due to excess insulin production. Patients with both focal and diffuse forms of CHI may have severe hypoglycaemia not responsive to medical therapies. Such patients require lesionectomy or subtotal pancreatectomy with a corresponding necessity for enhanced glycaemic monitoring during the peri-operative period. Subcutaneous Continuous Glucose Monitoring (CGM) provides real-time hi...

hrp0097p2-22 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2023

Hyperinsulinaemic Hypoglycaemia in Term Neonates Without Known Risk Factors Leading to Neurological Damage: A Case Series of 5 Patients From Two Regional Centres in the UK

O'Reilly Freya , Monaghan Marie , Moran Matthew , Gubaeva Diliara , Senniappan Senthil , Likeman Marcus , Giri Dinesh , Amin Sam

Background: Little is known about the prevalence of neonatal hypoglycaemia in the absence of known risk factors, nor its associated neurodevelopmental outcomes. Neurological harm from hyperinsulinism induced hypoglycaemia (HH) may be due to the direct effect of hypoglycaemia as well as its sequelae, such as seizures or apnoeas, leading to secondary insults such as hypoxic brain injury. With our case series we highlight such risks and propose changes to support...